April 11, 2025- BD announced U.S. Food and Drug Administration (FDA) 510(k) clearance for BD Phoenix™ M50 and BDXpert™ System on the BD Synapsys™ Informatics Solution, leveraging rapid identification (ID) and antimicrobial susceptibility testing (AST) algorithms to assist in the interpretation of complex diagnostic data to help ensure accurate and reliable diagnoses related to antimicrobial resistance (AMR).
BDXpert™ is an automated, rule-based system that analyzes ID and AST results from the
BD Phoenix™ M50 Automated Microbiology System, further enhancing its capabilities. By integrating with the BD Synapsys™ Informatics Solution, this system aids laboratorians in addressing ongoing challenges related to understaffing, increased testing demands and evolving susceptibility testing standards by helping streamline data management, helping reduce the potential for errors, and providing the delivery of critical test results and accurate information to clinicians.